• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon
EN

MIMETAS in consortium to develop in vitro placenta models

The most important organ in the human body

March 17, 2018 – MIMETAS is part of a consortium to develop in vitro placenta models. The objective of the iPlacenta project is to develop state-of-the-art models to mimic the placenta in vitro. This Huffington Post article stresses the importance of modeling what is probably the most important organ in the human body, giving life to us all.

The placenta rapidly develops throughout gestation and is a unique organ getting blood supply from both the mother and the child. It is made up of maternal and fetal vessels, with numerous highly branched villi lined with trophoblasts that facilitate gas, nutrient, and waste exchange.

Placenta-on-a-Chip

MIMETAS' OrganoPlate® technology offers unique functionalities, not possible with conventional 2D or 3D culture, allowing to better replicate the complex placenta tissue architecture. Currently, tissue culture using explants from the delivered placenta offers the only routine method to study the whole multicellular placenta ex vivo. This restricts our ability to understand the dynamic cellular interaction in normal and diseased placenta, since the explants are from delivered term placenta and are no longer under the same haemodynamic forces. Additionally, human tissues have to be obtained straight from delivery, limiting the availability and reproducibility.

The aim of the project is to develop a placenta-on-a-chip model and validate it in different labs. Within the project, young EU scientists will benefit from training in this rapidly growing field.

Partners and funding

Partners in the project are: Aston University, St Georges Hospital (UK), INSERM (FR), Katholieke Universiteit Leuven (BE), University College Cork (IE), University of Rostock (GER), University Hospital of Valencia (SP) and University of Torino (IT).

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 765274.

Sign up for our Newsletter

Cookies

May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all